rs5029939 — TNFAIP3

TNFAIP3 6q23 — The SLE-Risk Signal in the Immune Brake Locus

Deep in chromosome 6, within an intron of the TNFAIP3 gene, lies a variant that marks one of the strongest known single-SNP associations with systemic lupus erythematosus. The rs5029939 G allele does not change the A20 protein's amino acid sequence — instead, it tags a haplotype at the 6q23 locus that alters how effectively A20, the protein encoded by TNFAIP3¹¹ A20, the protein encoded by TNFAIP3
TNFAIP3 stands for TNF Alpha Induced Protein 3; A20 is the primary brake on NF-kB inflammatory signaling, terminating immune responses after they have served their purpose performs its job of shutting down inflammation.

The Mechanism

A20 is a ubiquitin-editing enzyme²² ubiquitin-editing enzyme
Ubiquitin is a small protein tag that cells attach to other proteins to control their fate — marking them for destruction, altering their activity, or changing their interactions with a dual function that makes it uniquely capable of terminating NF-kB signaling. Its N-terminal OTU domain strips activating K63-linked ubiquitin chains from inflammatory signaling proteins like RIP1, while its C-terminal zinc finger domain adds degradation-targeting K48-linked chains. This two-step process — deactivate then destroy — efficiently shuts down inflammatory cascades after infection or injury.

rs5029939 is an intronic variant and is not itself the causal mutation. It sits in strong linkage disequilibrium with functional variants at the 6q23 locus that influence A20 expression or activity — likely acting as a tag SNP for a haplotype carrying one or more regulatory changes. The 6q23 region is dense with independently associated signals: rs6920220 reduces TNFAIP3 transcription³³ rs6920220 reduces TNFAIP3 transcription
CRISPR editing studies show A-allele cells produce less TNFAIP3 mRNA, elevating NF-kB activity and pro-inflammatory cytokines, rs2230926 encodes the F127C missense variant that directly impairs A20 enzymatic activity, and rs5029939 marks a third, partially overlapping haplotype with its own independent SLE association. The net result of carrying the G allele at rs5029939 — whatever the precise mechanism — is an immune system predisposed to prolonged inflammatory signaling and loss of self-tolerance.

Beyond systemic immune effects, A20 plays a direct role in gut barrier integrity. TNFAIP3 maintains intestinal epithelial tight junctions⁴⁴ TNFAIP3 maintains intestinal epithelial tight junctions
A20 deubiquitinates occludin, a key tight junction protein, preventing its degradation and maintaining barrier function by regulating the ubiquitination of occludin. Reduced A20 function leads to increased intestinal permeability, linking TNFAIP3 haplotype risk directly to gut health.

The Evidence

The primary discovery came from a genome-wide association scan of 431 SLE cases and 2,155 controls⁵⁵ genome-wide association scan of 431 SLE cases and 2,155 controls
Followed by replication in additional cohorts; combined meta-analysis reached genome-wide significance with P=2.89×10⁻¹², which identified rs5029939 as the lead SLE signal at the TNFAIP3 6q23 locus (OR 2.29). The study simultaneously identified a second independent signal at the same locus — rs6920220, previously associated with rheumatoid arthritis — confirming that the 6q23 region carries distinct genetic variants that confer risk for different autoimmune diseases through partially overlapping mechanisms.

A landmark transancestral meta-analysis of 27,574 individuals⁶⁶ transancestral meta-analysis of 27,574 individuals
Included European ancestry, African-American, and Hispanic Amerindian cohorts genotyped on the Immunochip array confirmed rs5029939 association with SLE at OR 1.48 [95% CI 1.38–1.60], P=5×10⁻²⁹ — one of the most robustly replicated non-HLA SLE associations across ancestries. The variant's association with SLE extends to Sjogren's syndrome (OR 1.67 [1.40–1.99], P=8×10⁻⁹ per GWAS Catalog GCST002217), consistent with the shared autoimmune susceptibility architecture at this locus.

The G allele shows pronounced population stratification: approximately 3.3% in Europeans, 1.0% in East Asians, 36% in Africans, 7% in South Asians, and 6% in Latinos. This high frequency in African populations mirrors the pattern seen for rs2230926 (F127C), suggesting that African populations may carry a broader repertoire of TNFAIP3 risk haplotypes, possibly reflecting ancient balancing selection where some level of heightened immune reactivity conferred resistance to infectious pathogens at the cost of elevated autoimmune susceptibility.

Practical Implications

Carrying the G allele means your immune system is genetically primed for sustained NF-kB inflammatory signaling with elevated SLE risk (OR ~1.5–2.3 depending on the analysis) and elevated Sjogren's syndrome risk (OR ~1.7). For most G carriers, this manifests as modestly elevated lifetime autoimmune risk rather than inevitable disease — but targeted monitoring and NF-kB-modulating interventions are warranted.

The strongest interventional evidence targets the NF-kB pathway directly. The VITAL randomized trial of 25,871 participants⁷⁷ VITAL randomized trial of 25,871 participants
Randomized, double-blind, placebo-controlled trial over 5.3 years with 2-year post-trial follow-up found that vitamin D3 2,000 IU/day reduced incident autoimmune disease by 22% (HR 0.78) and omega-3 1g/day reduced it by 15%, with benefits persisting after supplementation ended. For G carriers whose primary risk is lupus and Sjogren's syndrome rather than RA, the SLE-specific monitoring imperative — regular ANA screening, UV protection, renal function checks — supplements these NF-kB-modulating strategies.

Curcumin (as bioavailable phytosome or piperine-enhanced formulations at 500–1,000 mg/day) is one of the most studied natural NF-kB inhibitors and merits consideration as a sustained supplement for carriers.

Interactions

rs5029939 is one of at least three independent autoimmune risk signals at the 6q23 TNFAIP3 locus. The rs6920220 A allele (reduces A20 expression) and rs2230926 G allele (F127C, impairs A20 enzymatic activity) represent mechanistically distinct sources of A20 dysfunction. Carriers of rs5029939 G who also carry rs6920220 A or rs2230926 G face compounded TNFAIP3 pathway disruption — impaired A20 function through multiple independent routes simultaneously.

PTPN22 R620W (rs2476601) acts through an independent mechanism — lowering the T-cell activation threshold — that converges with TNFAIP3 dysfunction to compound overall autoimmune susceptibility. The combination of rs5029939 G with PTPN22 risk alleles may be particularly relevant for SLE risk.

The TNFAIP3 locus also modulates gut barrier function through A20's regulation of occludin ubiquitination. NOD2 variants (rs2066844, rs2066845) act in the same NF-kB activation pathway in the gut; impaired A20 termination of NOD2-triggered signals could amplify Crohn's disease risk.